Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy

References

• Adi S, Adi H, Tang P, Traini D, Chan HK, Young P. Micro-particle corrugation, adhesion and inhalation efficiency. Eur J Pharm Sci 2008; 35: 12–18
   PubMed Web of Science ®Google Scholar
• Alhusban F, Seville PC. Carbomer – Modified spray-dried respirable powders for pulmonary delivery of salbutamol sulphate. J Microencapsul 2009; 26: 444–55
   PubMed Web of Science ®Google Scholar
• Armstrong DJ, Elliott PNC, Ford JL, Gadson D, McCarthy GP, Rostron C, Worsley MD. Poly(DL-lactic acid) microspheres incorporating histological dyes for intra-pulmonary histopathological investigations. J Pharm Pharmacol 1996; 48: 258–62
   PubMed Web of Science ®Google Scholar
• Berlinski A, Willis JR, Leisenring T. In-vitro comparison of 4 large-volume nebulisers in 8 hours of continuous nebulization. Respir Care 2010; 55: 1671–9
   PubMed Web of Science ®Google Scholar
• Bodmeier R, Wang J, Bhagwatwar H. Process and formulation variables in the preparation of wax microparticles by a melt dispersion technique. II. W/O/W multiple emulsion technique for water-soluble drugs. J Microencapsul 1992; 9: 99–107
   PubMed Web of Science ®Google Scholar
• Bousquillon C, Lombry C, Preat V, Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. J Pharm Sci 2001; 90: 2032–41
   PubMedGoogle Scholar
• Chmelik F, Doughty A. Objective measurements of compliance in asthma treatment. Ann Allergy 1994; 73: 527–32
   PubMedGoogle Scholar
• Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release 2005; 5: 79–90
   Google Scholar
• Corrigan DO, Healy AM, Corrigan OI. Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur J Pharm Biopharm 2006; 62: 295–305
   PubMed Web of Science ®Google Scholar
• Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: Recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002; 19: 425–98
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Crocetti JG, Smolensky MH. Circadian rhythms in pharmacokinetics and clinical effects of β-agonist, theophylline and anticholinergic medications in the treatment of nocturnal asthma. Chronobiol Int 1999; 16: 663–82
   PubMed Web of Science ®Google Scholar
• Dalpiaz A, Mezzena M, Scaturin A, Scalia S. Solid lipid microparticles for the stability enhancement of the polar drug N6-cyclopentyladenosine. Int J Pharm 2008; 355: 81–6
   PubMed Web of Science ®Google Scholar
• Darwis Y, Kellaway IW. Nebulisation of rehydrated freeze-dried beclomethasone diproprionate liposomes. Int J Pharm 2001; 215: 113–21
   PubMed Web of Science ®Google Scholar
• Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003; 14: 175–87
   Google Scholar
• Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868–71
   PubMed Web of Science ®Google Scholar
• El-Baseir MM, Kellaway IW. Poly(L-lactic acid) microspheres for pulmonary drug delivery: Release kinetics and aerosolisation studies. Int J Pharm 1998; 175: 135–45
   Web of Science ®Google Scholar
• European Pharmacopoeia. Preparation for inhalation: Aerodynamic assessment of fine particles7th. EDQM – Council of Europe, Strasbourg, France 2010
   Google Scholar
• Finlay WH, Wong JP. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int J Pharm 1998; 167: 121–7
   Web of Science ®Google Scholar
• Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. USA Patent No. 5250236, USA, 1993.
   Google Scholar
• Groneberg DA, Witt C, Wagner U, Chung KF, Fisher A. Fundamentals of pulmonary drug delivery. Respir Med 2003; 97: 382–7
   PubMed Web of Science ®Google Scholar
• Hong Y, Hu FQ, Yuan H. Effect of PEG 2000 on drug delivery characterization from solid lipid nanoparticles. Pharmazie 2006; 61: 312–15
   PubMed Web of Science ®Google Scholar
• Huang W-H, Yang Z-J, Wu H, Wong Y-F, Zhao Z-Z, Liu L. Development of liposomal salbutamol sulphate dry powder inhaler formulation. Biol Pharm Bull 2010; 33: 512–17
   PubMed Web of Science ®Google Scholar
• Jaspart S, Bertholet P, Piel G, Dogné JM, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 2007; 65: 47–56
   PubMed Web of Science ®Google Scholar
• Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: Formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv 2005; 2: 75–87
   PubMedGoogle Scholar
• Karathanasis E, Ayyagari AL, Bhavane R, Bellamkonda RV, Annapraganda AV. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J Control Release 2005; 103: 159–75
   PubMed Web of Science ®Google Scholar
• Kelly HW, Murphy S. Beta-adrenergic agonists for acute, severe asthma. Ann Pharmacother 1992; 26: 81–91
   PubMed Web of Science ®Google Scholar
• Kips JC, Pauwels RA. Long-acting inhaled β2-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164: 923–32
   PubMed Web of Science ®Google Scholar
• Learoyd TP, Burrows JL, French E, Seville PC. Sustained delivery of salbutamol and beclometasone from spray-dried double emulsions. J Microencapsul 2010; 27: 162–70
   PubMed Web of Science ®Google Scholar
• Malo JL, Cartier A, Merland N, Ghezzo H, Burek A, Morris J, Jennings BH. Four-times-a-day dosing frequency is better than twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide to control moderate to severe asthma. Am Rev Respir Dis 1989; 140: 624–8
   PubMedGoogle Scholar
• Mezzena M, Scalia S, Young PM, Traini D. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J 2009; 11: 771–8
   PubMed Web of Science ®Google Scholar
• Müller RH, Maaβen H, Weyhers F, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996; 138: 85–94
   Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid Lipid Nanoparticles (SLN) and Nanostructure Lipid Carrier (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131–55
   PubMed Web of Science ®Google Scholar
• Myers MA, Thomas DA, Straub L, Soucy W, Niven RW, Kaltenbach M, Hood CI, Schreier H, Gonzalez-Rothi RJ. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp Lung Res 1993; 19: 1–19
   PubMed Web of Science ®Google Scholar
• Nassimi M, Schleh C, Lauenstein HD, Hussein R, Hoymann HG, Koch W, Pohlmann G, Krug N, Sewald K, Rittinghausen S, et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm 2010; 75: 107–16
   PubMed Web of Science ®Google Scholar
• Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001; 14: S19–26
   PubMedGoogle Scholar
• Rytting E, Bur M, Cartier R, Bouyssou T, Wang X, Krüger Lehr C-M, Kissel T. In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. J Control Release 2010; 141: 101–7
   PubMed Web of Science ®Google Scholar
• Salama RO, Traini D, Chan HK, Young PM. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation. 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm 2008; 70: 145–52
   PubMed Web of Science ®Google Scholar
• Salama RO, Traini D, Chan HK, Young PM. Recent advances in controlled release pulmonary therapy. Curr Drug Deliv 2009a; 6: 404–14
   PubMedGoogle Scholar
• Salama RO, Traini D, Chan H-K, Sung A, Ammit AJ, Young PM. Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J Pharm Sci 2009b; 98: 2709–17
   PubMed Web of Science ®Google Scholar
• Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, Evrard B. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech 2003; 5: e27
   Google Scholar
• Scalia S, Mezzena M. Incorporation in lipid microparticles of the UVA filter, butyl methoxydibenzoylmethane combined with the UVB filter, octocrylene: Effect on photostability. AAPS PharmSciTech 2009; 10: 384–90
   PubMed Web of Science ®Google Scholar
• Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58: 996–1008
   PubMed Web of Science ®Google Scholar
• Sebti T, Amighi K. Preparation and in vivo evaluation of lipidic carriers and filers for inhalation. Eur J Pharm Biopharm 2006; 63: 51–8
   PubMed Web of Science ®Google Scholar
• Traini D, Young P. Delivery of antibiotics to the respiratory tract: An update. Expert Opin Drug Deliv 2009; 6: 897–905
   PubMed Web of Science ®Google Scholar
• Yu J, Chien YW. Pulmonary drug delivery:physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 1997; 14: 395–453
   PubMed Web of Science ®Google Scholar
• Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to the lung. Int J Pharm 1995; 124: 149–64
   Web of Science ®Google Scholar